MediciNova received positive Optical Coherence Tomography (OCT) results from the company’s SPRINT-MS Phase IIb trial of MN-166 (ibudilast) in multiple sclerosis subjects.

France-based MedDay Pharmaceuticals announced the company’s MED1003 failed to meet the primary and secondary endpoints in the second pivotal Phase III trial for progressive multiple sclerosis (MS).